Mineralys Therapeutics

Update in progress

MLYS (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Mineralys Therapeutics, Inc. is a biopharmaceutical company focused on medicines for diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, an oral, highly selective inhibitor of aldosterone synthase for cardiorenal conditions linked to excess aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. Formerly Catalys SC1, Inc., it changed its name in May 2020. Incorporated in 2019, it is headquartered in Radnor, Pennsylvania.

Company score

Sentiment: 0.49; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.53; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.11; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.18; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.34; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive